Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

With a new foreword by Nora Volkow, Director of the National Institute on Drug Abuse, this second edition of Office-Based Buprenorphine Treatment of Opioid Use Disorder provides updated information on evidence-based treatment for opioid use disorder (OUD)—an increasingly important topic as the epidemic of opioid misuse and overdose deaths grows in the United States. Bulleted clinical pearls at the end of each chapter, as well as specific clinical recommendations and detailed case discussions throughout, make it easier for readers to retain knowledge and integrate it into their clinical practice. The guide also features sample documentation and scales, including a treatment contract and a patient consent, that can be used to model documents in practice. This new edition of Office-Based Buprenorphine Treatment has been updated to reflect DSM-5 language, and two additional chapters have been included: one that addresses other pharmacotherapies useful in treating OUD, including methadone and naltrexone, and another that discusses OUD treatment specifically with regard to women’s health and pregnancy. A discussion of the Comprehensive Addiction and Recovery Act (CARA). Advice for working with Alcoholics Anonymous and Narcotics Anonymous. A discussion on integrating buprenorphine into residential and inpatient opioid treatment programs. -- Publisher

Opioid abuse --- Buprenorphine --- Analgesics --- Morphine --- Narcotic antagonists --- Opioid addiction --- Opioid habit --- Drug abuse --- Chemotherapy. --- Therapeutic use. --- Derivatives --- Opioid-Related Disorders --- Opiate Substitution Treatment. --- Medication Assisted Treatment of Opioid --- Opiate Medication-Assisted Treatment --- Opioid Medication Assisted Treatment --- Opioid Replacement Therapy --- Opioid Substitution Therapy --- Opioid Substitution Treatment --- Opiate Replacement Therapy --- Medication-Assisted Treatment, Opiate --- Opiate Medication Assisted Treatment --- Opiate Medication-Assisted Treatments --- Opiate Replacement Therapies --- Opiate Substitution Treatments --- Opioid Replacement Therapies --- Opioid Substitution Therapies --- Opioid Substitution Treatments --- Replacement Therapy, Opiate --- Replacement Therapy, Opioid --- Substitution Therapy, Opioid --- Substitution Treatment, Opiate --- Substitution Treatment, Opioid --- Therapy, Opioid Substitution --- Methadone --- 6029-M --- Buprenex --- Buprenorphine Hydrochloride --- Buprex --- Prefin --- RX-6029-M --- Subutex --- Temgesic --- Temgésic --- 6029 M --- 6029M --- Hydrochloride, Buprenorphine --- RX 6029 M --- RX6029M --- Opiate Substitution Treatment --- Addiction, Opioid --- Dependence, Opioid --- Opiate Abuse --- Opioid Abuse --- Opioid Addiction --- Opioid Dependence --- Opiate Addiction --- Opiate Dependence --- Abuse, Opiate --- Abuse, Opioid --- Abuses, Opiate --- Abuses, Opioid --- Addiction, Opiate --- Addictions, Opioid --- Dependence, Opiate --- Dependences, Opioid --- Opiate Abuses --- Opioid Abuses --- Opioid Addictions --- Opioid Dependences --- Opioid Related Disorders --- Opioid-Related Disorder --- Analgesics, Opioid --- Narcotics --- Opioid Maintenance Treatment --- Maintenance Treatment, Opioid --- Opioid Maintenance Treatments --- Treatment, Opioid Maintenance --- Opioid Misuse --- Opioid Use Disorder --- Prescription Opioid Abuse --- Prescription Opioid Misuse --- Abuse, Prescription Opioid --- Disorder, Opioid Use --- Misuse, Opioid --- Misuse, Prescription Opioid --- Opioid Abuse, Prescription --- Opioid Misuses --- Opioid Use Disorders --- Prescription Opioid Abuses --- Prescription Opioid Misuses --- drug therapy. --- therapeutic use. --- drug therapy --- therapeutic use

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The interest in opioids such as morphine, the prototypical opioid ligand, has been maintained through the years. The identification of endogenous opioids and their receptors (mu, delta, kappa, and nociceptin), molecular cloning, and the elucidation of the crystal structures of opioid receptors represent key milestones in opioid research. The opioid system modulates numerous pharmacological responses, with therapeutic (i.e., analgesia) and detrimental side effects (i.e., addiction). The medical use and misuse of opioids have dramatically increased, leading to the 21st century opioid crisis. This book presents recent developments in opioid drug discovery, specifically in the medicinal chemistry and pharmacology of new ligands targeting the opioid receptors as effective and safe therapeutics for human diseases. Furthermore, it draws a special attention to advancing concepts and strategies in opioid drug discovery to mitigate opioid liabilities. The diversity among the discussed topics is a testimony to the complexity of the opioid system, which results from the expression, regulation, and functional role of ligands and receptors. The array of multidisciplinary research areas illustrates the rapidly developing basic research and translational activities in opioid drug discovery. This book will serve as a useful reference while also stimulating continued research in the chemistry and pharmacology of opioids and their receptors, with the prospect of developing improved therapies for human diseases, but also improving health and quality of life in general.

opioid receptors --- neurokinin-1 receptor --- peptide synthesis --- receptor binding studies --- functional assay --- writhing test --- tolerance --- Leu-enkephalin --- beta-arrestin --- mu opioid receptor --- delta opioid receptor --- biased signaling --- DADLE --- ischemia --- plasma stability --- morphinan --- BNTX --- δ opioid receptor antagonist --- 1H-NMR experiments --- mechanism elucidation --- peripheral antinociception --- 14-methoxycodeine-6-O-sulfate --- codeine-6-O-sulfate --- opioid peptides and peptidomimetics --- DAMGO --- DALDA --- [Dmt1]DALDA --- KGOP01 --- binding --- molecular docking --- structure-activity relationships --- β2-amino acids --- β2-Homo-amino acids --- µ-opioid receptor --- opioid peptides --- TAPP --- racemic synthesis of β2-amino acids --- peripheral µ-opioid receptors --- analgesia --- peripheral analgesic tolerance --- dysbiosis --- opioid --- bifunctional ligands --- (−)-N-phenethylnorhydromorphone analogs --- [35S]GTPgammaS assay --- forskolin-induced cAMP accumulation assays --- β-arrestin recruitment assays --- MOR and DOR agonists --- respiratory depression --- bias factor --- molecular modeling &amp --- simulation --- δ opioid receptor --- NTI derivative --- sulfonamide --- inverse agonist --- neutral antagonist --- agonist --- opioids --- mu receptor --- opioid side effects --- biased agonism --- partial agonism --- zerumbone --- chronic constriction injury (CCI) --- allodynia --- hyperalgesia --- potassium channels --- over-the-counter drugs --- misuse --- abuse --- opioid drugs --- pharmacology --- codeine --- dihydrocodeine --- loperamide --- opioid peptide --- macrocyclic tetrapeptide --- multifunctional ligands --- kappa opioid receptor --- analgesics --- opioid liabilities --- μ opioid receptor --- receptor model --- biased ligands --- dependence --- pain therapy --- neonatal opioid withdrawal syndrome --- naltrexone --- 6β-naltrexol --- buprenorphine --- G-protein bias --- arrestin recruitment --- respiration --- mitragynine --- heteromer --- internalization --- primary hippocampal culture --- lysosomes --- µ opioid receptor --- molecular dynamics --- docking --- interaction fingerprints --- biased agonists --- SR-17018 --- PZM21 --- morphine --- fentanyl --- diphenethylamines --- design and synthesis --- structure–activity relationships --- partial agonist --- biased agonist --- antagonist --- binding affinity --- selectivity --- n/a